The Immune Tolerance Institute this week said Aaron Kantor joined the company as chief scientific officer.
Prior to ITI, Kantor was executive director of cell and molecular biology for biomarker discovery sciences at Pharmaceutical Product Development, a contract research organization. Before that, he was manager for the rare cell program and cell depletion therapeutic program at AmCell.